Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rituxan Is On Target (Price Wise) As Multiple Sclerosis Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec says rituximab would be priced comparably to other MS therapies.

You may also be interested in...



Rituxan Adds Third NHL Indication In 2006

The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.

Rituxan Adds Third NHL Indication In 2006

The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.

Biogen Idec Plans Multiple Sclerosis Portfolio Expansion

Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel